secwatch.observer — SEC 8-K summary
======================================

Issuer:     BeOne Medicines Ltd. (ONC)
CIK:        0001651308
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001651308-23-000163
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BeiGene Q3 revenue $781M (+102% YoY); net income of $215M vs loss of $558M last year
--------------------------------------------------------------------------------

- Global product sales up 70% to $595M; BRUKINSA sales $358M (+130%) led by US launch momentum.
- Net income $215M vs net loss $558M in Q3 2022; operating loss improved by $304M YoY.
- Total revenue $781M (+102%); US revenue $398M, China $288M, Europe $86M.
- Gross margin improved to 83.8% from 78.1% on higher-mix BRUKINSA and lower tislelizumab costs.
- Cash $3.2B; TEVIMBRA approved in EU, US BLA accepted for ESCC with PDUFA July 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651308/000165130823000163/0001651308-23-000163-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651308/000165130823000163/bgne-20231109.htm
  HTML page:      https://secwatch.observer/filing/0001651308-23-000163

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer